BACKGROUND The ABSORB III Pharmacokinetic (PK) study is a prospective, open-label, non-randomized sub-study of the ABSORB III randomized trial designed to determine the PK of everolimus delivered by the Absorb bioresorbable vascular scaffold (BVS) in subjects who only receive Absorb BVS with a maximum treatment of two de novo coronary artery lesions. The pharmacokinetic profile of Absorb BVS has not previously been described.
BACKGROUND The ABSORB III Pharmacokinetic (PK) study is a prospective, open-label, non-randomized sub-study of the ABSORB III randomized trial designed to determine the PK of everolimus delivered by the Absorb bioresorbable vascular scaffold (BVS) in subjects who only receive Absorb BVS with a maximum treatment of two de novo coronary artery lesions. The pharmacokinetic profile of Absorb BVS has not previously been described.
METHODS Twelve subjects were enrolled at two sites in the United States. Subjects received one (n¼8) or two (n¼4) Absorb BVS with diameters of 2.5., 3.0 or 3.5 mm and lengths of 8, 12, 18 or 28 mm. The total everolimus dose received ranged from 181 to 443 mg. Blood samples (arterial or venous) were collected from the subjects preprocedure and at fifteen time points post-procedure (10 and 30 minutes, 1, 2, 4, 6, 12, 24, 48, 72, 96, 120 (day 5) , 168 (day 7), 336 (day 14), and 720 hours (day 30) after the last scaffold implantation). The concentration of everolimus in the blood was determined by Liquid Chromatography-Mass Spectrometry/Mass Spectrometry assay. The lower limit of quantification was 0.1 ng/mL. The blood concentrationtime data were subjected to non-compartmental methods to determine PK parameters (Cmax, tmax, AUC, t1/2).
RESULTS Everolimus blood concentrations increased rapidly after Absorb BVS deployment, reaching maximum concentration between 0.17 and 2.37 hours (tmax), declining thereafter with a terminal halflife ranging between 45.9 and 115 hours. By 4 hours, everolimus blood concentrations were below 3 ng/ml (the chronic therapeutic level necessary to prevent organ rejection in transplant patients) in all subjects. Everolimus blood concentrations were low but measurable for up to 168 hours (7 days) after last scaffold deployment. The maximum observed everolimus concentration (Cmax) increased with dose and ranged from 1.085 to 4.460 ng/ml across the dose range studied. Similarly, individual AUC (AUC24h: 12.09 to 44.22 ng*h/mL; AUClast: 25.37 to 104.6 ng*h/mL; AUC0-N: 33.15 to 120.8 ng*h/mL) increased proportionally with total scaffold dose.
CONCLUSIONS The local arterial delivery of everolimus and systemic exposure increased proportionally with dose and rapidly declined thereafter. The everolimus PK profiles seen with Absorb BVS are safe, and are similar to previously reported profiles for the cobalt chromium everolimus-eluting XIENCE stent. BACKGROUND A post marketing clinical follow-up study was conducted evaluating the continued safety and effectiveness of the CEmark approved DESolve Ò Novolimus Eluting Bioresorbable Coronary Scaffold System (NEBCSS) (Elixir Medical, Sunnyvale, CA), a drugeluting bioresorbable scaffold combining a PLLA-based scaffold coated with a biodegradable polylactide-based polymer and Novolimus, a macrocyclic lactone mTOR inhibitor. The drug dose is 5 mg per mm of scaffold length and the device is available in multiple diameters (2.5, 3.0, 3.25 and 3.5) and lengths (14, 18 and 28 mm).
METHODS A total of 100 patients were treated with the DESolve NEBCSS in de novo lesion coronary artery lesions with a reference vessel diameter between 2.25 and 3.5 mm and treatable with a single scaffold between 14 and 28 mm in length. Patient data for the clinical endpoints of major adverse cardiac events (MACE) defined as: cardiac death, target vessel MI, clinically-indicated target lesion revascularization (TLR); target vessel revascularization and stent thrombosis are to be analyzed at 1, 6, 12 months and annually through 5 years. The study was approved the local Ethics Committees and all patients provided informed consent.
RESULTS
Patients were enrolled over a one year period at 10 sites in Germany, and Italy. After the index procedure, patients were contacted at 30 days and 6 months either via an office visit or telephonically. Patient demographic, lesion characteristics and clinical results though 6 months will be presented.
CONCLUSIONS The DESolve NECSS post-marketing clinical follow-up study demographics and lesion characteristics overview and clinical results through 6 months will be presented. 
